The trial is currently recruiting patients who have experienced a recurrence of ovarian, fallopian, or primary peritoneal cancer six months or more after receiving platinum-based chemotherapy. Maintenance treatments (also known as targeted treatments)work on specific genes and proteins that are involved in the growth and survival of cancer cells. T…

Researchers in this trial are looking to find out whether a new way of giving carboplatin chemotherapy (adaptive therapy "AT") is as safe as and more effective than the current standard way of giving carboplatin in women with advanced recurrent ovarian cancer.Recurrent ovarian cancer is usually treated with chemotherapy. The chemotherapy aims to ki…

Olaparib is a type of targeted treatment known as a PARP inhibitor. It blocks an enzyme called PARP, which helps damaged cancer cells to repair themselves. When PARP doesn't work the cancer cells won't be able to repair themselves and will die. Because of this, drugs such as olaparib are known to lengthen the amount of time between receiving chemot…

This trial looks to answer the question as to whether two different types of anti-cancer drugs, given as maintenance treatment are: safe effective well-tolerated Maintenance treatment is a type of targeted therapy that is given to try to prevent or delay the cancer's return after it has responded to chemotherapy. …